<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Renee Z Rinaldi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Salicylazosulfapyridine (<a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, SSZ) is a nonbiologic (conventional or traditional) disease-modifying antirheumatic drug (DMARD) that was originally proposed as a treatment for rheumatoid arthritis (RA) because of its antiinflammatory and antimicrobial activities [<a href="#rid1">1,2</a>]. It has also been used for other inflammatory joint disorders and for inflammatory bowel disease (IBD).</p><p>Initial studies in the 1940s suggested a beneficial effect in patients with RA, but the drug's efficacy was challenged by the findings of a negative, small, open-label 1949 report, which was influential despite a flawed study design [<a href="#rid3">3,4</a>]. Additionally, the introduction of cortisone during this period, an event then hailed as a modern medical miracle, further dampened enthusiasm for the use of SSZ in RA. However, a resurgence of interest in SSZ as a therapeutic agent for rheumatic disorders occurred after beneficial results were reported in a trial performed in the late 1970s and in the first placebo-controlled trial in 1983, and it is widely available [<a href="#rid5">5,6</a>].</p><p>The pharmacology, dosing, and adverse effects of SSZ as used in the treatment of RA and other forms of inflammatory arthritis are discussed here. The use and relative efficacy of SSZ in the management of RA and other conditions are presented separately. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a> and  <a class="medical medical_review" href="/d/html/111392.html" rel="external">"Treatment of arthritis associated with inflammatory bowel disease", section on 'Management of peripheral arthritis'</a> and  <a class="medical medical_review" href="/d/html/105691.html" rel="external">"Treatment of peripheral spondyloarthritis", section on 'Resistant to initial therapy'</a> and  <a class="medical medical_review" href="/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H6980055"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> (SSZ) is a prodrug composed of 5-aminosalicylic acid (5-ASA) linked to sulfapyridine through an azo bond (<a class="graphic graphic_figure graphicRef76617" href="/d/graphic/76617.html" rel="external">figure 1</a>). Approximately 30 percent of orally administered SSZ, which therapeutically is a relatively inactive chemical, is rapidly absorbed by the small bowel and is then returned, largely unaltered, via the enterohepatic circulation into the bile. Thus, approximately 90 percent of the ingested drug reaches the large intestine as an intact molecule [<a href="#rid3">3,7</a>].</p><p>In the colon, SSZ is reduced by the bacterial enzyme azoreductase to its two components, sulfapyridine and 5-ASA. Thus, coliform bacteria are necessary to reduce the relatively inactive parent drug to its active moieties. Nearly all of the sulfapyridine is absorbed, while 5-ASA is largely excreted in the feces, consistent with the utility of 5-ASA in inflammatory bowel disease (IBD).</p><p>Sulfapyridine is subsequently metabolized in the liver via hydroxylation and acetylation. The half-life of these components is prolonged in slow acetylators, a property which may affect toxicity but not efficacy [<a href="#rid3">3,7</a>].</p><p>No major drug-drug interactions have been reported [<a href="#rid3">3</a>]. However, in vitro studies demonstrated that SSZ can interfere with cellular uptake of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), a folate analogue, by the reduced folate carrier (RFC), which transports both folates and MTX across the cell membrane [<a href="#rid8">8</a>]. This does not appear to adversely affect the clinical efficacy of most combination regimens of disease-modifying antirheumatic drugs (DMARDs) that include SSZ [<a href="#rid9">9,10</a>]. The combination of MTX and SSZ was found less effective than MTX combined with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ). This lack of an additive or synergistic effect may be due to inhibition by SSZ of MTX uptake at the RFC.</p><p>It has also been shown in in vitro studies that SSZ downregulates multidrug resistance-associated protein (MRP)-1, a protein that exports <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> from the cell, resulting in higher intracellular levels of HCQ, which could explain the finding in clinical trials that the same inhibitory effect of SSZ on MTX cellular transport did not detract from the proven overall efficacy of MTX-SSZ-HCQ triple therapy [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Studies directly comparing the efficacy of sulfapyridine with 5-aminosalicylic acid (5-ASA) suggest that sulfapyridine is the active moiety in patients with rheumatoid arthritis (RA), rather than 5-ASA, which is the active metabolite in the treatment of inflammatory bowel disease (IBD) [<a href="#rid11">11-14</a>]. The mechanism of action of sulfapyridine in RA has not been identified, and a positive effect due to the parent molecule alone cannot be entirely excluded [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a> (SSZ) and sulfapyridine have antiinflammatory, immunosuppressive, and other effects.</p><p>Sulfapyridine, like SSZ [<a href="#rid15">15</a>], may have disease-modifying effects as its administration in patients with RA is associated with decreases in the erythrocyte sedimentation rate (ESR) and serum concentrations of C-reactive protein (CRP) [<a href="#rid12">12,13</a>]. However, there is little interest in further study of sulfapyridine alone because of potential toxicity issues, and the parent molecule remains the well-established agent used therapeutically.</p><p>There are several plausible mechanisms of action. One is the inhibition of nuclear factor-kappa B (NFkB). This protein, which is also suppressed by glucocorticoids, induces the transcription of central mediators of the immune response. An in vitro study found that the administration of SSZ strongly inhibited NFkB-dependent transcription in colonic cells [<a href="#rid16">16</a>]. Interestingly, these actions were unique to SSZ and were not observed with sulfapyridine or 5-ASA, thereby suggesting that the parent molecule may have important antiinflammatory properties. SSZ may also inhibit osteoclast formation via modulatory effects on the receptor activator of NFkB (RANK), osteoprotegerin (OPG), and RANK-ligand [<a href="#rid17">17</a>].</p><p>In addition, SSZ can inhibit tumor necrosis factor (TNF)-alpha expression via apoptosis of macrophages [<a href="#rid18">18</a>]. Sulfapyridine may reduce secretion of inflammatory cytokines such as interleukin (IL)-8 and monocyte chemoattractant protein (MCP)-1 [<a href="#rid14">14</a>]. Another study has suggested that SSZ and its metabolites preferentially suppress B-cell function but not T-cell function [<a href="#rid19">19</a>], while other data have indicated that SSZ may exert immunoregulatory effects that alter lymphocytes in the mucosa of the small intestine [<a href="#rid20">20</a>].</p><p>An additional mechanism that has been proposed is through increased production of adenosine at sites of inflammation, which has been suggested to be an antiinflammatory property of SSZ that it shares with another effective antirheumatic drug, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) [<a href="#rid21">21,22</a>].</p><p>Since sulfapyridine is a sulfonamide, an antibacterial effect has been entertained; however, the observation that other sulfonamides are ineffective in RA makes this hypothesis unlikely. One 24-week study, for example, directly compared sulfapyridine (1.25 g per day) with cotrimoxazole (<a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, 480 mg three times daily) in patients with RA [<a href="#rid23">23</a>]. Disease activity either was unchanged or had worsened among patients treated with cotrimoxazole; by comparison, improvement was observed in those administered sulfapyridine.</p><p>In another study, SSZ and its metabolites (5-aminosalicylic acid and sulfapyridine) exerted an additive and dose-dependent inhibitory effect on arachidonic acid-induced platelet aggregation in vitro, which was comparable to that of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. This represents a potential mechanism that may contribute to the previously described cardioprotective effect of SSZ in patients with inflammatory arthritis [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3280668490"><span class="h1">GENETIC POLYMORPHISMS AFFECTING SSZ EFFICACY</span><span class="headingEndMark"> — </span>A number of studies have examined the effect of genetic polymorphisms on the efficacy of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ) in rheumatoid arthritis (RA), although this remains a developing area. There is evidence that some genetic polymorphisms can affect clinical responsiveness, but these variants are not routinely assessed clinically and do not influence clinical practice.</p><p>In one study, polymorphic variations in the <em>MTR</em>, <em>SLC19A1</em>, and <em>TYMS</em> genes (all components of the folate pathway) were associated with better clinical response to combination disease-modifying antirheumatic drug (DMARD) regimens containing <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) and SSZ [<a href="#rid25">25</a>]. Another study noted an association between the <em>MTHFR 677T</em> allele and statistically significant increased frequency of remission [<a href="#rid26">26</a>].</p><p>Another study assessed the <em>MDR-1</em> gene product, P-glycoprotein, one of the most important transporters for drug delivery in humans. The TT-genotype of the <em>3435C&gt;T MDR-1</em> gene polymorphism was associated with higher remission rates in rheumatoid patients treated with either MTX and <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> or SSZ [<a href="#rid27">27</a>].</p><p>A meta-analysis of 1077 patients indicates that the N-acetyltransferase 2 slow acetylator genotype is associated with an increased risk of adverse drug reactions, compared with patients who were fast or intermediate acetylators [<a href="#rid28">28</a>].</p><p>Studies using human cell cultures have suggested that T cells may develop resistance to SSZ by overexpression of a drug efflux pump, the multidrug resistance transporter BRCP/ABCG2 [<a href="#rid29">29,30</a>]. Though this finding may be clinically relevant, there is no evidence that loss of effectiveness in patients with RA is mediated in this manner.</p><p class="headingAnchor" id="H363400849"><span class="h1">DOSING AND MONITORING</span></p><p class="headingAnchor" id="H3529977472"><span class="h2">Pretreatment testing</span><span class="headingEndMark"> — </span>A complete blood count (CBC), liver transaminases, and creatinine levels should be obtained prior to beginning treatment with <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ) and after significantly increasing the dose. (See <a class="local">'Dosing, monitoring, and dose adjustment'</a> below.)</p><p>We also screen patients at high risk for glucose-6-phosphate dehydrogenase (G6PD) deficiency before initiating therapy, and we avoid this drug in those patients who are deficient because of the increased risk of hemolytic anemia that may be associated with the use of SSZ in patients with this condition.</p><p>G6PD deficiency is global in its distribution but varies between different ethnicities. As examples, it is more common in African Americans, groups originating from the Mediterranean region or the Middle East, South African Black populations, and Brazilians of African ancestry, as well as other groups. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Epidemiology'</a>.)</p><p>There are conflicting reports regarding the safety of SSZ and the degree of risk associated with its use in deficient patients [<a href="#rid31">31,32</a>]; thus, some experts consider it as "probably safe," and screening is not universally advocated. G6PD deficiency is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p class="headingAnchor" id="H1107471364"><span class="h2">Dosing, monitoring, and dose adjustment</span><span class="headingEndMark"> — </span>After baseline screening, the dose of SSZ should be increased gradually with regular laboratory monitoring to minimize the risk of adverse effects when beginning therapy [<a href="#rid33">33</a>] (see <a class="local">'Pretreatment testing'</a> above and <a class="local">'Adverse effects'</a> below). We generally initiate therapy at a dose of 500 mg daily for the first week and subsequently increase the dose by 500 mg daily on a weekly basis until a dose of 2 g daily is achieved.</p><p>Several reasonable approaches have been suggested for monitoring [<a href="#rid34">34,35</a>]. We check the CBC one week after each dose increase (before the next dose adjustment). During the first three months of therapy and when the dose is increased, evaluation of CBC, liver transaminases, and creatinine levels should occur every two to four weeks. During the third through sixth months of therapy, levels should be monitored every 8 to 12 weeks, and, after six months, levels should be monitored every 12 weeks [<a href="#rid34">34</a>]. We generally do not adjust the dose, but do monitor regularly as described, in patients with mild renal impairment; in patients with severe chronic kidney disease, we consult with the patient's nephrologist to determine the most appropriate dosing regimen. Observations from one small case series suggest that in patients undergoing hemodialysis, SSZ may be efficacious and tolerated in low doses (500 to 1000 mg daily) with careful monitoring, but additional evidence of the safety of this approach is needed [<a href="#rid36">36</a>].</p><p>The dose of SSZ can be lowered to 1500 or 1000 mg per day if the patient develops mild toxicity (see <a class="local">'Adverse effects'</a> below). The dose can be increased to a maximum of 3 g daily, usually in divided doses, in patients who fail to respond to 2 g daily and who are without significant side effects.</p><p>This approach to titration and monitoring is consistent with the 2008 American College of Rheumatology (ACR) guidelines for the use of nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) and with the 2012 and 2015 updates of these recommendations [<a href="#rid34">34,37,38</a>].</p><p class="headingAnchor" id="H4"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Adverse reactions, including idiosyncratic and dose-related effects, are common with <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ); relatively common among these are gastrointestinal, central nervous system, cutaneous, and hematologic adverse effects. These abnormalities sometimes result in drug discontinuation. However, in usual doses, SSZ is generally relatively well tolerated by most patients with rheumatoid arthritis (RA).</p><p>Approximately 20 to 25 percent of patients withdraw from clinical trials because of intolerable side effects [<a href="#rid3">3</a>]. Two-thirds of such withdrawals result from symptoms due to gastrointestinal and headaches, and approximately 4 to 5 percent of withdrawals are because of rash [<a href="#rid3">3</a>].</p><p>All of the adverse drug reactions described for SSZ are similar in patients with and without RA. The side effects are either idiosyncratic (eg, hypersensitivity-related or immune-related) or dose-related [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiosyncratic effects</strong> – Idiosyncratic effects can occur, which require immediate discontinuation of the drug and appropriate therapeutic interventions, depending upon the manifestation; patients with this type of adverse effect should not be rechallenged with the drug. Such reactions include skin reactions, including rare instances of toxic epidermal necrolysis and Stevens-Johnson syndrome (see  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>); hepatitis (see <a class="local">'Liver function abnormalities'</a> below); pneumonitis; agranulocytosis (see <a class="local">'Leukopenia and agranulocytosis'</a> below); aplastic anemia; and hemolytic anemia. Hemolytic anemia may be more common in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals but can also occur in patients on SSZ without this genetic variant [<a href="#rid32">32</a>]. (See <a class="local">'Pretreatment testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-related side effects</strong> – Dose-related side effects include gastrointestinal upset, central nervous system symptoms, and some less severe hematologic toxicities. Symptoms and laboratory findings of such involvement include anorexia, headache, nausea, vomiting, diarrhea, gastric distress, leukopenia, hemolytic anemia, macrocytosis, and, rarely, megaloblastic anemia. These problems may resolve with dose reduction.</p><p></p><p>One study evaluated the side effects and long-term use of SSZ among several hundred patients with RA in whom the drug was administered as a first-line agent for early disease (defined as less than 12 months of disease duration and no prior use of disease-modifying antirheumatic drugs [DMARDs]) [<a href="#rid33">33</a>]. A retention rate of 50 percent at two years was observed among patients administered SSZ, compared with only 20 percent for those given <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ). Forty-seven of 186 subjects (25 percent) withdrew because of adverse drug reactions; the majority withdrew within the first three months of the initiation of therapy.</p><p>The risk of adverse effects appears to be at least partly genetically determined. As an example, among 144 Japanese patients with RA treated with SSZ, those with N-acetyltransferase genotypes that resulted in slow acetylation of SSZ were more likely to have a side effect than those with fast acetylators of SSZ (63 and 8 percent, respectively) [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Liver function abnormalities</span><span class="headingEndMark"> — </span>SSZ may induce a specific syndrome characterized by fever, rash, and markedly abnormal liver function tests. Among such patients, the drug should be immediately discontinued, and the patient should not be rechallenged [<a href="#rid41">41</a>]. Patients should be warned about the possible induction of this syndrome since it may be mistaken and ignored as an intercurrent viral illness.</p><p>In one case series, the frequency of serious hepatotoxicity with SSZ was estimated at 0.4 percent of all treated patients [<a href="#rid42">42</a>]. Increased serum aminotransferase levels with SSZ may be more likely to develop in certain settings, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Serologic evidence of chronic viral hepatitis – When SSZ was given to 9 patients with and 18 patients without serologic evidence of chronic hepatitis B or C virus infection, an increase in serum aminotransferase levels was more common in those chronically infected (56 versus 17 percent) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant use of SSZ and <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> – An increased risk of transaminase elevation was noted when SSZ and isoniazid were used in the setting of tuberculosis prophylaxis in patients with RA [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Leukopenia and agranulocytosis</span><span class="headingEndMark"> — </span>Adverse effects of SSZ on white blood cells (WBC) may be either idiosyncratic or dose-related. Most episodes of leukopenia, which occur in 1 to 2 percent of patients, are mild and transient, but life-threatening agranulocytosis may also occur [<a href="#rid45">45,46</a>]. Since the number of circulating neutrophils is usually much higher than the number of lymphocytes, most leukopenic patients are neutropenic, although leukopenia may be due to either neutropenia or lymphopenia; as a result, the terms leukopenia, neutropenia, and granulocytopenia are often used interchangeably. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a> and  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Introduction'</a>.)</p><p>Patients with leukopenia may require adjustment in drug dosing, although precise levels for such dose adjustment for SSZ have not been established. Our approach in patients with mild leukopenia (total WBC of less than approximately 4000) is to temporarily discontinue SSZ and then to resume treatment when the WBC improves, with a dose reduction and careful weekly monitoring for several weeks with gradually increasing monitoring intervals. SSZ should be discontinued permanently if severe leukopenia develops (total WBC of less than 3000 or absolute neutrophil count of less than 1500), and weekly monitoring of cell counts should be performed until they stabilize in a normal range.</p><p>Serious episodes of agranulocytosis, when they do occur, are usually observed within the first three months and often within the first six weeks of therapy [<a href="#rid2">2,46</a>]. Agranulocytosis may be caused by immune-mediated destruction of circulating neutrophils by drug-induced antibodies or by direct toxic effects upon marrow granulocytic precursors. Agranulocytosis caused by a hypersensitivity reaction requires drug discontinuation without rechallenge.</p><p>Concurrent use of SSZ and <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> may result in a greater depression of neutrophil counts than that which occurs with the use of either agent alone. This was noted in a 2005 US Food and Drug Administration (FDA) warning in the prescribing information for etanercept that stated that the combination resulted in a mild decrease in mean neutrophil counts when compared with groups treated with etanercept or SSZ alone. However, the clinical significance of this finding and whether it applies to other TNF inhibitor combinations with SSZ is unknown. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Neutropenia'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Pregnancy and reproduction</span><span class="headingEndMark"> — </span>SSZ may cause reversible oligospermia and reduced male fertility; it is generally considered safe during pregnancy and breastfeeding. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases", section on 'Sulfasalazine'</a> and  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Sulfasalazine'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Other adverse events</span><span class="headingEndMark"> — </span>Case reports have demonstrated possible relationships between SSZ use and the development of granulomatosis with polyangiitis, reversible encephalopathy, Epstein-Barr virus-associated hypersensitivity syndrome, and hemophagocytic syndrome [<a href="#rid47">47-50</a>].</p><p>The rheumatoid nodulosis sometimes observed with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) therapy does not appear to occur with SSZ [<a href="#rid51">51</a>], and some reports have suggested that use of SSZ may reduce the size of rheumatoid nodules [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Desensitization</span><span class="headingEndMark"> — </span>In patients with sensitivity to SSZ, desensitization can often be accomplished [<a href="#rid53">53,54</a>]. Desensitization is primarily performed in patients with a history of rash to another sulfonamide; it should <strong>not</strong> be attempted in patients with a history of agranulocytosis. Desensitization should be performed in collaboration with an expert in this technique, typically an allergist. (See  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy", section on 'Options for future treatment'</a> and  <a class="medical medical_review" href="/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a>.)</p><p class="headingAnchor" id="H1606691214"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/512.html" rel="external">"Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/513.html" rel="external">"Patient education: Rheumatoid arthritis treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Studies directly comparing the efficacy of the two components of <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ), sulfapyridine and 5-aminosalicylic acid (5-ASA), suggest that sulfapyridine is the active moiety in patients with rheumatoid arthritis (RA), unlike in patients with inflammatory bowel disease (IBD), in which 5-ASA is the active metabolite. Benefit in patients with RA is largely attributed to sulfapyridine, although the parent molecule may also have a role. Immunoregulatory effects of SSZ on the mucosa of the small intestine have also been observed. Sulfapyridine is metabolized in the liver via hydroxylation and acetylation, and the half-life of these components is prolonged in slow acetylators, a property which may affect toxicity but not efficacy. No major drug-drug interactions have been reported. (See <a class="local">'Pharmacology'</a> above and <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose of SSZ should be increased gradually with regular laboratory monitoring to minimize the risk of adverse effects. A complete blood count (CBC), liver transaminases, and creatinine levels should be obtained prior to beginning treatment with SSZ, after significantly increasing the dose, and periodically during therapy, especially during the first three months following initiation of SSZ. The usual starting dose is 500 mg daily, and the usual maximum dose administered is 2 to 3 g daily in divided doses. (See <a class="local">'Dosing and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse reactions are common with SSZ. Approximately 20 to 25 percent of patients withdrew from clinical trials because of intolerable side effects. Two-thirds of such withdrawals resulted from symptoms due to gastrointestinal and central nervous system toxicity, and approximately 4 to 5 percent of withdrawals were because of rash. However, SSZ is generally relatively well tolerated by most patients with RA. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The side effects of SSZ are either idiosyncratic (eg, hypersensitivity-related or immune-related) or dose-related (see <a class="local">'Adverse effects'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Idiosyncratic effects include skin reactions, hepatitis, pneumonitis, agranulocytosis, aplastic anemia, and hemolytic anemia. Hemolytic anemia may be more common in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. When such reactions occur, the drug should be immediately stopped, and the patient should not be rechallenged.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-related side effects include gastrointestinal upset, central nervous system symptoms, and some less severe hematologic toxicities. Symptoms and laboratory findings of such involvement include anorexia, headache, nausea, vomiting, diarrhea, gastric distress, leukopenia, hemolytic anemia, and megaloblastic anemia. These problems may resolve with dose reduction.</p><p></p><p class="headingAnchor" id="H544181809"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael H Weisman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Amos RS. The history of the use of sulphasalazine in rheumatology. Br J Rheumatol 1995; 34 Suppl 2:2.</a></li><li><a class="nounderline abstract_t">SVARTZ N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948; 4:180.</a></li><li><a class="nounderline abstract_t">Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.</a></li><li><a class="nounderline abstract_t">Sinclair RJ, Duthie JJ. Salazopyrin in the Treatment of Rheumatoid Arthritis. Ann Rheum Dis 1949; 8:226.</a></li><li><a class="nounderline abstract_t">McConkey B, Amos RS, Durham S, et al. Sulphasalazine in rheumatoid arthritis. Br Med J 1980; 280:442.</a></li><li><a class="nounderline abstract_t">Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983; 287:1102.</a></li><li><a class="nounderline abstract_t">Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2:7.</a></li><li><a class="nounderline abstract_t">Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130.</a></li><li><a class="nounderline abstract_t">O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287.</a></li><li><a class="nounderline abstract_t">O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164.</a></li><li><a class="nounderline abstract_t">Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995; 34 Suppl 2:16.</a></li><li><a class="nounderline abstract_t">Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985; 290:1535.</a></li><li><a class="nounderline abstract_t">Taggart AJ, Neumann VC, Hill J, et al. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? Drugs 1986; 32 Suppl 1:27.</a></li><li><a class="nounderline abstract_t">Volin MV, Campbell PL, Connors MA, et al. The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol 2002; 73:84.</a></li><li><a class="nounderline abstract_t">van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1:1036.</a></li><li><a class="nounderline abstract_t">Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101:1163.</a></li><li><a class="nounderline abstract_t">Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004; 50:3831.</a></li><li><a class="nounderline abstract_t">Rodenburg RJ, Ganga A, van Lent PL, et al. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000; 43:1941.</a></li><li><a class="nounderline abstract_t">Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2002; 2:631.</a></li><li><a class="nounderline abstract_t">Kanerud L, Scheynius A, Hafström I. Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis. Arthritis Rheum 1994; 37:1138.</a></li><li><a class="nounderline abstract_t">Cronstein BN. Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum 2004; 50:2041.</a></li><li><a class="nounderline abstract_t">Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101:295.</a></li><li><a class="nounderline abstract_t">Astbury C, Hill J, Bird HA. Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine. Ann Rheum Dis 1988; 47:323.</a></li><li><a class="nounderline abstract_t">MacMullan PA, Madigan AM, Paul N, et al. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2016; 35:447.</a></li><li><a class="nounderline abstract_t">James HM, Gillis D, Hissaria P, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35:562.</a></li><li><a class="nounderline abstract_t">Pawlik A, Kurzawski M, Gawronska-Szklarz B, et al. The effect of 677C&gt;T and 1298A&gt;C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. Braz J Med Biol Res 2009; 42:660.</a></li><li><a class="nounderline abstract_t">Drozdzik M, Rudas T, Pawlik A, et al. The effect of 3435C&gt;T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 2006; 62:933.</a></li><li><a class="nounderline abstract_t">Yee J, Kim SM, Han JM, et al. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep 2020; 10:3658.</a></li><li><a class="nounderline abstract_t">van der Heijden J, de Jong MC, Dijkmans BA, et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 2004; 63:138.</a></li><li><a class="nounderline abstract_t">van der Heijden J, de Jong MC, Dijkmans BA, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004; 63:131.</a></li><li class="breakAll">http://www.g6pd.org (Accessed on May 31, 2013).</li><li><a class="nounderline abstract_t">Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33:713.</a></li><li><a class="nounderline abstract_t">van Riel PL, van Gestel AM, van de Putte LB. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2:40.</a></li><li><a class="nounderline abstract_t">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a class="nounderline abstract_t">Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008; 47:924.</a></li><li><a class="nounderline abstract_t">Akiyama Y, Sakurai Y, Kato Y, et al. Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis. Mod Rheumatol 2014; 24:285.</a></li><li><a class="nounderline abstract_t">Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.</a></li><li><a class="nounderline abstract_t">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016; 68:1.</a></li><li class="breakAll">Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM (Eds), Marcel Dekker, New York 1998. p.165.</li><li><a class="nounderline abstract_t">Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002; 29:2492.</a></li><li><a class="nounderline abstract_t">Fuchs HA. Use of sulfasalazine in rheumatic diseases. Bull Rheum Dis 1997; 46:3.</a></li><li><a class="nounderline abstract_t">Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008; 9:48.</a></li><li><a class="nounderline abstract_t">Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18:363.</a></li><li><a class="nounderline abstract_t">Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62:1241.</a></li><li><a class="nounderline abstract_t">Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293:420.</a></li><li><a class="nounderline abstract_t">Farr M, Scott DG, Bacon PA. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986; 32 Suppl 1:49.</a></li><li><a class="nounderline abstract_t">Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis? Scand J Rheumatol 2008; 37:72.</a></li><li><a class="nounderline abstract_t">Mut SE, Kutlu G, Ucler S, et al. Reversible encephalopathy due to sulfasalazine. Clin Neuropharmacol 2008; 31:368.</a></li><li><a class="nounderline abstract_t">Komatsuda A, Okamoto Y, Hatakeyama T, et al. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol 2008; 27:395.</a></li><li><a class="nounderline abstract_t">Alokaily F, AlKathiri R, AlKathiri S, Alrashidi S. A limited form of granulomatosis with polyangiitis in an ulcerative colitis patient receiving sulfasalazine. Saudi Med J 2022; 43:105.</a></li><li><a class="nounderline abstract_t">Capell HA. Clinical efficacy of sulphasalazine--a review. Br J Rheumatol 1995; 34 Suppl 2:35.</a></li><li><a class="nounderline abstract_t">Englert HJ, Hughes GR, Walport MJ. Sulphasalazine and regression of rheumatoid nodules. Ann Rheum Dis 1987; 46:244.</a></li><li><a class="nounderline abstract_t">Bax DE, Amos RS. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis 1986; 45:139.</a></li><li><a class="nounderline abstract_t">Bojanini L, Sacco K, Maya Villamizar JJ, et al. Successful Rapid Oral Desensitization to Sulfasalazine: An 11-Step Protocol. J Clin Rheumatol 2021; 27:S428.</a></li></ol></div><div id="topicVersionRevision">Topic 7524 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535643" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The history of the use of sulphasalazine in rheumatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18915673" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The treatment of rheumatic polyarthritis with acid azo compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133974" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sulphasalazine in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18623820" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Salazopyrin in the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6102877" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sulphasalazine in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138117" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535652" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sulphasalazine: mechanism of action in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248210" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609945" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115219" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535642" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2860942" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Which component of sulphasalazine is active in rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2877851" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231210" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565997" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486988" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15593184" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014343" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12013503" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Regulation of human B cell function by sulfasalazine and its metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7914408" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248200" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435300" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3284488" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253538" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322994" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578646" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of 677C&gt;T and 1298A&gt;C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932953" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of 3435C&gt;T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107440" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722201" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722200" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722200" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20701405" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535648" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512708" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940305" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252022" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473917" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545825" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545825" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12465141" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366125" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of sulfasalazine in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18405372" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895374" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644871" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2874863" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2877853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18189198" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050416" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reversible encephalopathy due to sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952482" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35022291" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A limited form of granulomatosis with polyangiitis in an ulcerative colitis patient receiving sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535647" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical efficacy of sulphasalazine--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883940" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sulphasalazine and regression of rheumatoid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2868699" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32028308" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful Rapid Oral Desensitization to Sulfasalazine: An 11-Step Protocol.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
